New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial

NCT ID NCT05593666

Completed Disease control Sponsor: Drugs for Neglected Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 28. The trial is complete, and results will show how safe and effective the new drug is compared to the current standard.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

visceral leishmaniasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY VISCERAL LEISHMANIASIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.

LXE408 for Visceral Leishmaniasis Trial (NCT05957978)

Contacts and locations

Show contact details

Locations

DrugsNeglectedD Investigational Site

Bīhar, India
DrugsNeglectedD Investigational Site

Patna, India